Active Pharmaceutical Ingredients (APIs)

Lonza Adds More Building Blocks for the Healthcare Continuum

Japan’s Changing Pharmaceutical Landscape

PMC Buys Isochem’s Pharma Business

Ireland’s Thriving Pharma and Chemicals Producers Optimistic about Brexit

Pfizer Sells Stake in Chinese JV with Hisun

Piramal Invests $55 million on API Expansions

Emirates Skycargo: Revalidation of pharma certification at Dubai hub

The EXCiPACT Certification Scheme

Science that Enables Solutions for Clean Air, Improved Health and Sustainable Use of Resources

APIs: Evaluating Supply and Demand

The Expanding Role of Contract Manufacturing

SK Capital Changes Tack on Archroma

Cambrex Expands Charles City API Plant

Lonza Buys Swiss Micronization Technology Specialist Micro-Macinazione

Neuland Laboratories Opens Dedicated Process Engineering Lab

Trinseo to Acquire Italy’s API

Cambrex Invests in Swedish cGMP Facility

Meeting Customers’ Changing Needs

Catalysts for More Efficient Processes

Umicore Facility in Argentinia Passes new European cGMP Audit

Transatlantic Deal Simplifies Pharma Inspections

Ferak Berlin Receives GMP Certification

Lonza Captures Capsugel for $5.5 Billion

The Winning Formula

Cambrex Validates Milan API Pilot Plant

BASF Inaugurates China PVP Plant

Cambrex Announces Investment & Expansion

ISPE Recognizes Leaders in Drug Shortage Prevention

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

A New Pathway

The Possibilities Of Peptides

The Winning Formula

Bridging the Innovation Gap

Piramal Adds Ash Stevens for $53 Million

FDA Warns GSK on Contamination at UK Plant